MAP2K7 and melanoma: Aside from the use of MEK inhibitors to target BRAF-mutated melanomas, there is also preclinical evidence that indicates vulnerability to MEK inhibitors in a not insignificant number of melanomas which do not present BRAF V600 mutations, called wild-type BRAF melanomas (especially in NRAS-Q61-mutant tumors), and also in BRAF/NRAS wild-type melanomas, together with melanomas harboring non-V600 BRAF mutations [33,40].